company mission and therapeutic theory for fibrotic diseases
Very little changed between January 24, 2018 and January 12, 2019. MDI Therapeutics kept the same core theory: fibrosis shares a common engine in the fibrin fibrotic matrix, and serpin biology can be used to prevent fibrosis and possibly reverse it. The mechanism stayed the center of the pitch, not a side note. The company description also stayed stable. In both entries, MDI presents itself as a discovery-stage company using a proprietary platform to find small-molecule and protein drug candidates for fibrotic diseases. The 2018 language adds a broader ambition, to become a global leader in fibrosis therapeutics, but that is a positioning line, not a change in scientific thesis. What changed, then, is mostly trimming and emphasis. The 2019 version is slightly tighter and more operational, with less grand framing and the same biological claim. We do not see evidence here of a shift in mission, target class, or therapeutic logic. Evidence is thin because both entries are website self-descriptions, and both say nearly the same thing. There is no new trial data, program update, or mechanistic revision in this record, so the safest read is continuity with minimal rhetorical adjustment.